BHVN Biohaven Pharmaceutical Holding Co Ltd

Price (delayed)

$147.15

Market cap

$10.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.81

Enterprise value

$11.05B

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including ...

Highlights
BHVN's revenue is up by 17% QoQ
The company's gross profit rose by 16% QoQ
The debt has soared by 179% year-on-year and by 21% since the previous quarter
Biohaven Pharmaceutical Holding's equity has plunged by 76% YoY and by 73% from the previous quarter

Key stats

What are the main financial stats of BHVN
Market
Shares outstanding
71.49M
Market cap
$10.52B
Enterprise value
$11.05B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
12.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.85
Earnings
Revenue
$859.68M
EBIT
-$779.23M
EBITDA
-$755.79M
Free cash flow
-$558.52M
Per share
EPS
-$14.81
Free cash flow per share
-$7.86
Book value per share
-$11.27
Revenue per share
$12.1
TBVPS
$18.46
Balance sheet
Total assets
$1.39B
Total liabilities
$2.19B
Debt
$764.98M
Equity
-$800.93M
Working capital
$502.39M
Liquidity
Debt to equity
-0.96
Current ratio
1.75
Quick ratio
1.35
Net debt/EBITDA
-0.7
Margins
EBITDA margin
-87.9%
Gross margin
85.6%
Net margin
-108%
Operating margin
-74.4%
Efficiency
Return on assets
-82.3%
Return on equity
N/A
Return on invested capital
-77.1%
Return on capital employed
-109.1%
Return on sales
-90.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BHVN stock price

How has the Biohaven Pharmaceutical Holding stock price performed over time
Intraday
0.12%
1 week
0.78%
1 month
1.1%
1 year
18.15%
YTD
6.78%
QTD
0.99%

Financial performance

How have Biohaven Pharmaceutical Holding's revenue and profit performed over time
Revenue
$859.68M
Gross profit
$736.14M
Operating income
-$639.91M
Net income
-$928.79M
Gross margin
85.6%
Net margin
-108%
BHVN's operating margin has surged by 81% year-on-year but it is down by 5% since the previous quarter
The net margin has soared by 77% year-on-year but it has declined by 14% since the previous quarter
Biohaven Pharmaceutical Holding's net income has decreased by 33% QoQ and by 4.5% YoY
The operating income has declined by 23% since the previous quarter but it is up by 14% year-on-year

Growth

What is Biohaven Pharmaceutical Holding's growth rate over time

Valuation

What is Biohaven Pharmaceutical Holding stock price valuation
P/E
N/A
P/B
N/A
P/S
12.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.85
The EPS has declined by 25% since the previous quarter and by 2.8% year-on-year
Biohaven Pharmaceutical Holding's equity has plunged by 76% YoY and by 73% from the previous quarter
The price to sales (P/S) is 32% less than the last 4 quarters average of 18.0
BHVN's revenue is up by 17% QoQ

Efficiency

How efficient is Biohaven Pharmaceutical Holding business performance
The return on sales has surged by 78% year-on-year but it has declined by 20% since the previous quarter
BHVN's ROIC has soared by 59% year-on-year but it is down by 12% since the previous quarter
BHVN's ROA is up by 23% year-on-year but it is down by 15% since the previous quarter

Dividends

What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BHVN.

Financial health

How did Biohaven Pharmaceutical Holding financials performed over time
The total assets is 37% smaller than the total liabilities
BHVN's total liabilities has surged by 76% year-on-year and by 19% since the previous quarter
The total assets has surged by 64% year-on-year
The debt is 196% greater than the equity
The debt has soared by 179% year-on-year and by 21% since the previous quarter
Biohaven Pharmaceutical Holding's equity has plunged by 76% YoY and by 73% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.